How to Buy Teladoc Stock in New Zealand in 2025

What is Teladoc?

How much is the Teladoc stock?

The price of Teladoc stock is steady this week. Currently trading at around $7.00 USD, Teladoc has seen little change in the last 24 hours, while the weekly performance also remains broadly flat.

As Teladoc is not yet profitable, its P/E ratio is not applicable, and it pays no dividend. With a stock beta of 1.51, Teladoc tends to show higher-than-average volatility—something NZ investors may wish to consider as they weigh both the risks and long-term opportunities in the virtual health sector.

Our full analysis of the Teladoc stock

We have thoroughly reviewed Teladoc’s latest quarterly results, assessed the stock’s price trajectory over the past three years, and run a comprehensive suite of quantitative and qualitative screens—including financial, technical, market, and peer group analysis—through our proprietary algorithms. As the virtual healthcare sector enters a period of strategic realignment and renewed growth themes, Teladoc Health (NYSE: TDOC) appears to be at a critical inflection point. So, why might Teladoc stock once again become a strategic entry point into the digital health sector in 2025?

Recent Performance and Market Context

Teladoc shares are currently trading at around $7.00 USD, representing a 12-month decline of approximately 36% and sitting close to the lower end of the 52-week range ($6.35–$15.21). This recent underperformance is set against a backdrop of broad technology stock volatility and a recalibration in risk appetite globally, including across Australasian portfolios. Yet, in the past several months, several high-profile developments signal a potential bottoming and reversal in market sentiment:

• Leadership Change: The June 2024 appointment of CEO Chuck Divita III brings proven operational expertise and a renewed focus on execution, a catalyst often associated with turnaround stories.
• Strategic M&A: Acquisitions of UpLift and Catapult Health expand Teladoc’s suite of mental health and virtual care solutions, directly addressing the fastest-growing segments of digital health.
• Marquee Partnerships: Deepening integration with Amazon’s Health Benefits Connector provides unprecedented distribution channels and pricing power.
• Macroeconomic Tailwinds: As healthcare costs rise and shortages in primary care persist globally—including in NZ’s own health system—the value proposition for telemedicine continues to strengthen.

These events, layered atop a healthcare sector viewed as resilient to cyclical downturns and exposed to demographic tailwinds, underpin a context where Teladoc appears well-placed for recovery and renewed growth.

Technical Analysis

Current technical indicators suggest that Teladoc is in a mature corrective phase, potentially setting the stage for an accumulation pattern and first signs of bullish reversal:

• Relative Strength Index (RSI): At 41.76, Teladoc’s RSI is in neutral territory, skirting oversold levels—a classic precursor to renewed buying interest.
• MACD: With a marginally negative MACD of -0.11, the stock is exhibiting waning bearish momentum. A cross above the signal line would further reinforce a bottoming thesis.
• Moving Averages: The shares are trading below their short- (20-day: $7.79), medium- (50-day: $9.57), and long-term (200-day: $9.21) moving averages, confirming that the downward pressure is well-priced and hinting at reversal potential should price action move above support at $6.97.
• Support and Resistance: Robust support at $6.97, with the next resistance at $7.18—an initial move above this level would likely attract momentum-driven inflows, especially from technical traders.
• Momentum Structure: The prolonged decline, coupled with sustained volume (see next section), may be indicative of capitulation—a necessary condition for a durable bottom and renewed uptrend.

Overall, the technical set-up appears to be shifting, with factors converging that historically precede recoveries in high-beta tech stocks.

Fundamental Analysis

Despite ongoing losses, Teladoc’s fundamentals reflect a business that is rapidly scaling, innovating, and positioned for normalization of margins:

• Revenue Profile: Q1 2025 revenues reached $629.4 million (vs. $648.0 million in Q1 2024), showing only a modest 3% year-on-year decline. Notably, the Integrated Care segment grew 3% to $389.5 million, offsetting weaker results from BetterHelp.
• EBITDA Profits: Adjusted EBITDA continues to print positive at $311 million (12.1% margin), reflecting a disciplined cost approach and the capacity for operating leverage as revenues stabilize.
• Valuation Perspective: At current levels (~$1.22 billion market capitalization), Teladoc is trading at just 0.47x trailing revenues—a deep discount to historic multiples and peer benchmarks in the sector. While still loss-making (no reported P/E), this marks a uniquely attractive entry point on a price-to-sales basis, particularly given the company’s global footprint and recurring revenue streams.
• Strategic Strengths:
• Technological Leadership: Ongoing innovation (notably AI integration) and a global network spanning 130+ countries.
• Market Position: Genuine category leader in enterprise and direct-to-consumer telehealth, with a powerful brand and first-mover advantage.
• Scalable Business Model: With broad coverage across B2B and consumer segments, Teladoc is well-placed to capitalize on growing remote-care adoption worldwide, including within NZ’s evolving healthcare ecosystem.

Volume and Liquidity

Robust average daily volume (~6.08 million shares) adds significant market confidence and liquidity, crucial for institutional and retail investors alike. This volume, even as the share price finds support, suggests active price discovery and limits downside from illiquidity. The stock’s float remains large enough to facilitate dynamic revaluation, particularly as narrative shifts or catalysts materialize.

Catalysts and Positive Outlook

Several forward-looking developments strongly support the case for upside rerating over the coming quarters:

• Product and Service Expansion: Recent acquisitions (UpLift, Catapult Health) augment the core proposition, diversifying revenue sources and fortifying Teladoc’s position in high-growth areas such as digital mental health and chronic care.
• Strategic Partnerships: Integration with Amazon and growing collaboration with established enterprise payers amplifies market reach—an essential differentiator as competition in the sector intensifies.
• ESG and Innovation: Teladoc is advancing both operational sustainability and healthcare access through increased digitization, drawing increasing institutional interest given the rise of ESG-focused mandates.
• Positive Market Dynamics: Secular trends—aging populations, clinician shortages, and cost pressure on health systems—remain deeply supportive. In NZ, this resonates with ongoing public debate and policy focus on next-generation health services.
• Leadership Reset: The fresh mandate for CEO Chuck Divita signals new strategic priorities—often a harbinger of more agile execution, portfolio optimization, and targeted investments.

Analyst price targets now cluster in the $8.88–$9.60 zone, implying 29–37% upside from current levels, validating the case for a significant re-rating as execution and sentiment recover.

Investment Strategies

With these factors in mind, Teladoc displays compelling attributes for a broad spectrum of investors:

• Short-Term Perspective: Technical indicators suggest a consolidation near multi-year lows. Aggressive traders could seek entry during the current base-building phase, targeting a breakout above resistance at $7.18 for initial momentum.
• Medium-Term Perspective: Upcoming earnings releases, ongoing integration of acquisitions, and rollout of new B2B partnerships act as imminent catalysts. Investors may choose to accumulate positions ahead of these events, taking advantage of a reversion-to-mean scenario.
• Long-Term Perspective: For patient capital, Teladoc’s unrivalled international scale, innovation pipeline, and exposure to a structurally expanding TAM (total addressable market) offer a uniquely attractive foundation. Current valuation metrics provide strong downside protection for those with a three-to-five-year time horizon, particularly as margin normalization trends re-emerge.

The stock’s attractive risk/reward is further enhanced by its high beta, ensuring that positive newsflow or sector rerating could drive outsized moves in a relatively short period.

Is it the Right Time to Buy Teladoc?

To summarise, Teladoc sits at a rare confluence of technical, fundamental, and strategic opportunity. Its valuation is compelling relative to both historic norms and sector peers; recent corporate actions and leadership changes signal renewed momentum; and secular, demographic, and technological trends all combine to support robust long-term growth in virtual healthcare. With robust liquidity, a dynamic pipeline of strategic catalysts (including next-generation service launches and deepening blue-chip partnerships), and the stock positioned near historical support levels, the case for renewed investor focus is well-grounded.

In our expert view, Teladoc’s fundamental transformation, underpinned by both internal and external drivers, justifies renewed interest from investors seeking technology exposure within healthcare—especially as the sector re-emerges as a growth engine and the business pivots towards sustainable profitability.

For New Zealand investors looking for an undervalued, globally exposed digital health leader with high leverage to future growth, Teladoc appears to represent an excellent opportunity at a key inflection point in the company’s journey. The balance of risk and reward, underpinned by operational and sectoral tailwinds, suggests that Teladoc Health may be entering a promising new bullish phase—one that merits close and ongoing consideration in forward-looking portfolios.

How to buy Teladoc stock in New Zealand?

Buying Teladoc (TDOC) shares online is both simple and secure for New Zealand investors when you use a regulated broker. You can choose between two main methods: purchasing real Teladoc shares (“spot buying”) for long-term ownership, or trading share CFDs (Contracts for Difference), which let you speculate on the price movements without owning the underlying stock. Each approach has its own advantages and risk profile, making it important to choose the one that fits your goals best. To help you make an informed decision, you’ll find a detailed broker comparison further down the page.

Spot Buying

A cash purchase (or "spot buying") means you acquire real Teladoc shares that are legally registered in your name via your broker’s platform. This method is well suited to investors who want to actually own Teladoc stock and benefit from any price appreciation over time. Standard fees typically include a fixed commission per transaction, often ranging from NZ$3 to NZ$10 per order on Kiwi-friendly platforms.

Example

Suppose Teladoc is trading at US$7.00 per share. With an investment of NZ$1,000 (about US$600 at recent rates), after a brokerage fee of NZ$5, you could buy approximately 85 shares.
- Gain scenario: If Teladoc’s share price rises by 10%, the market value of your shares increases to around NZ$1,100.
- Result: That’s a NZ$100 gross profit—+10% on your investment (excluding any currency conversion fees).

CFD Trading

CFD trading on Teladoc shares allows you to speculate on price movements without owning the underlying shares. With CFDs, you can use leverage to amplify your exposure, but you’ll incur costs such as the spread (difference between buy/sell price) and overnight financing fees for positions held beyond one day.

Example

If you open a CFD position in Teladoc with NZ$1,000 and apply 5x leverage, your market exposure is NZ$5,000.
- Gain scenario: If Teladoc’s price rises by 8%, your leveraged position would deliver a 40% gain (8% × 5), equalling NZ$400 (excluding spreads and overnight costs).
- Please note, leverage can magnify losses as well as gains.

Final Advice

Before investing, always compare broker platforms’ fees, spreads, and available features to find the best fit for your needs. The right method—spot buying or CFDs—depends on your investment objectives, risk tolerance, and whether you prefer long-term ownership or more active, speculative trading. You’ll find a comprehensive broker comparison further down this page to guide your choice.

Our 7 tips for buying Teladoc stock

The latest news about Teladoc

Teladoc Health has expanded its virtual care offering through recent acquisitions and strategic technology partnerships. Recently, Teladoc completed key deals—namely the acquisition of mental health platform UpLift and Catapult Health—strengthening its multi-specialty telehealth ecosystem and enhancing its capabilities in mental health and corporate care. These expansions broaden its global reach and reinforce its ability to offer integrated care solutions, a segment which saw a 3% revenue increase in Q1 2025. Such diversification could appeal to New Zealand users and institutional clients seeking comprehensive digital health services from established global leaders with proven technological innovation.

The appointment of Chuck Divita III as CEO in June 2024 signals a new phase of strategic leadership for Teladoc. Divita's background in healthcare finance and operations introduces focused expertise at a crucial time, as the company seeks to reverse recent revenue declines and improve profitability. The fresh leadership may foster renewed confidence among institutional investors in New Zealand and internationally, particularly as the company’s turn-around strategy emphasizes operational efficiency and value creation in the virtual health sector, a theme closely monitored by health investors in the region.

Teladoc’s integration with Amazon’s Health Benefits Connector highlights a high-profile partnership driving technological relevance. This integration positions Teladoc as a preferred virtual care provider within Amazon’s fast-growing ecosystem and signals cross-market acceptance of its platform. For New Zealand financial analysts, this is particularly relevant as it demonstrates alignment with technology sector best practices and opens opportunities for future collaborations or exposure in other geographies, reinforcing the stock’s positioning amidst shifting digital health delivery models.

Despite a 3% annual sales decline, Teladoc’s Q1 2025 revenues met analyst expectations and its Integrated Care segment continues to grow. First quarter 2025 results reported $629.4 million in revenue, aligning with consensus and showing resilience amid industry-wide telehealth normalization. The Integrated Care segment, relevant for employer health plans and international clients, including potential APAC partners, delivered solid 3% annual growth. This suggests a sturdy foundation for further international expansion—including into Oceania—given Teladoc’s active presence in over 130 countries.

Analyst consensus maintains a cautious 'Hold' on Teladoc but implies upside potential based on the current share price. The average 12-month price target ranges from $8.88 to $9.60, representing a 29–37% increase over recent trading levels around $7.00 USD. While the company’s long-term losses and the decline in consumer mental health demand (BetterHelp) dampen sentiment, New Zealand investors may find the risk-reward profile increasingly constructive as Teladoc consolidates its offerings and leverages strategic partnerships, with positive developments and technical signals suggesting possible future recovery.

FAQ

P. Laurore

Finance expert

Co-founder of HelloSafe and holder of a Master's degree in finance, Pauline has recognised expertise in personal finance, which she uses to help users better understand and optimise their financial choices. At HelloSafe, Pauline plays a key role in designing clear, educational content on savings, investments and personal finance. Passionate about financial education, Pauline strives, with every piece of content she oversees, to provide reliable, transparent and unbiased information for independent and informed financial management. To this end, she has tested over 100 trading platforms to help internet users make the right choices.